Aplaviroc

DB06497InvestigationalSmall molecule

A spiro-diketo-piperazine; a potent noncompetitive allosteric antagonist of the CCR5 receptor with concomitantly potent antiviral effects for HIV-1.

Mechanism: GW873140 is a novel CCR5 receptor antagonist that binds specifically to human CCR5. It binds to human CCR5 with a unique profile as evidenced by the selective inhibition of monoclonal antibody binding. One of the many ways in which CCR5 inhibitors differ from the currently available classes of HIV drugs is that they bind to the host (CCR5 receptor), the cell, target rather than to the viral enzymes in cells like the CD4 cell.
Curator reviewed
Primary indication: Investigated for use/treatment in HIV infection.Curator reviewed
Formula / weight: C₃₃H₄₃N₃O₆ · 577.722 g/mol (avg)
Code names: AK-602 · GW-873140 · ONO-4128

Resolves to

Compound

Structure

InChIKeyGWNOTCOIYUNTQP-FQLXRVMXSA-NSMILES[H][C@@]1(NC(=O)C2(CCN(CC3=CC=C(OC4=CC=C(C=C4)C(O)=O)C=C3)CC2)N(CCCC)C1=O)[C@H](O)C1CCCCC1

Targets

What you can answer from here — as of September 19, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

558Drug interactionsStructured to mechanism, not free text

5Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Aplaviroc, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.